Cargando…

Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis

BACKGROUND: Originator trastuzumab (Herceptin®; H) is an antibody-targeted therapy to treat patients with human epidermal growth factor receptor 2-positive (HER2+) early breast cancer (EBC). We investigated the overall survival (OS) advantage conferred by the addition of H to chemotherapy for HER2+...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wilson, Florence R., Coombes, Megan E., Brezden-Masley, Christine, Yurchenko, Mariya, Wylie, Quinlan, Douma, Reuben, Varu, Abhishek, Hutton, Brian, Skidmore, Becky, Cameron, Chris
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237027/ https://www.ncbi.nlm.nih.gov/pubmed/30428932 http://dx.doi.org/10.1186/s13643-018-0854-y

Ejemplares similares

Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis
por: Wilson, Florence R., et al.
Publicado: (2017)

Psoriasis Induced by Trastuzumab (Herceptin®)
por: Kim, Dae Hun, et al.
Publicado: (2013)

Plant-Made Trastuzumab (Herceptin) Inhibits HER2/Neu+ Cell Proliferation and Retards Tumor Growth
por: Komarova, Tatiana V., et al.
Publicado: (2011)

Radiation Recall Reaction Induced by Adjuvant Trastuzumab (Herceptin)
por: Chung, Caroline, et al.
Publicado: (2009)

Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin(®)) in patients with HER2-positive metastatic breast cancer
por: Chen, Xiaoying, et al.
Publicado: (2019)

Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin(®)) in patients with HER2‑positive metastatic breast cancer
por: Chen, Xiaoying, et al.
Publicado: (2019)

Safety of trastuzumab (Herceptin(®)) during pregnancy: two case reports
por: Goodyer, Matthew J, et al.
Publicado: (2009)

A population-based comparison of treatment, resource utilization, and costs by cancer stage for Ontario patients with HER2-positive breast cancer
por: Brezden-Masley, Christine, et al.
Publicado: (2020)

Safety survey on infusion reaction and cardiac dysfunction when switching from reference trastuzumab (HERCEPTIN(®)) to biosimilar trastuzumab (Trastuzumab‑NK) in the treatment of HER2‑positive breast cancer
por: Abe, Tomoya, et al.
Publicado: (2023)

Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin™) in HER2-overexpressing breast cancer cells
por: Menendez, Javier A, et al.
Publicado: (2007)

A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with hormone receptor-positive/HER2-negative breast cancer
por: Brezden-Masley, Christine, et al.
Publicado: (2020)

Comparative Nonclinical Assessments of the Proposed Biosimilar PF-05280014 and Trastuzumab (Herceptin(®))
por: Hurst, Susan, et al.
Publicado: (2014)

Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase
por: Shpilberg, O, et al.
Publicado: (2013)

Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
por: Müller, Volkmar, et al.
Publicado: (2018)

Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas
por: Martin-Castillo, Begoña, et al.
Publicado: (2015)

Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer
por: Wilson, Florence R., et al.
Publicado: (2017)

Herceptin-sensitivity of HER2-transgenic mouse mammary tumors
por: Schwall, RH, et al.
Publicado: (2003)

Serological Her2/neu-determination in patients receiving Herceptin(®)
por: Thomas, A, et al.
Publicado: (2001)

Herceptin (trastuzumab) in patients who overexpress Her-2 and have failed multiple chemotherapy regimens for advanced breast cancer: a pragmatic study
por: Westman, G
Publicado: (2000)

Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptin(®)), a HER2-targeted monoclonal antibody, in patients with a variety of solid tumors
por: Quartino, Angelica L., et al.
Publicado: (2018)

The evaluation of left ventricular function for patients being considered for, or receiving Trastuzumab (Herceptin) therapy
por: Fox, K F
Publicado: (2006)

Drifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilar
por: Kim, Seokkyun, et al.
Publicado: (2017)

Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective
por: Henning, Jan-Willem, et al.
Publicado: (2023)

In silico design, construction and cloning of Trastuzumab humanized monoclonal antibody: A possible biosimilar for Herceptin
por: Akbarzadeh-Sharbaf, Soudabeh, et al.
Publicado: (2012)

Update on HER-2 as a target for cancer therapy: Herceptin in the clinical setting
por: Miles, David W
Publicado: (2001)

Novel Toll-like receptor-4 deficiency attenuates trastuzumab (Herceptin) induced cardiac injury in mice
por: Yousif, Nasser Ghaly, et al.
Publicado: (2011)

Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective
por: Ferrario, Cristiano, et al.
Publicado: (2022)

A population‐based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with triple‐negative breast cancer
por: Brezden‐Masley, Christine, et al.
Publicado: (2020)

Presence of HER4 associates with increased sensitivity to Herceptin™ in patients with metastatic breast cancer
por: Sassen, Andrea, et al.
Publicado: (2009)

Kinetic Modeling of DUSP Regulation in Herceptin-Resistant HER2-Positive Breast Cancer
por: Buiga, Petronela, et al.
Publicado: (2019)

An Experimental Analysis of the Molecular Effects of Trastuzumab (Herceptin) and Fulvestrant (Falsodex), as Single Agents or in Combination, on Human HR+/HER2+ Breast Cancer Cell Lines and Mouse Tumor Xenografts
por: Chen, Qing, et al.
Publicado: (2017)

Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm
por: Yang, Charlie, et al.
Publicado: (2023)

Reciprocal Regulation of Annexin A2 and EGFR with Her-2 in Her-2 Negative and Herceptin-Resistant Breast Cancer
por: Shetty, Praveenkumar K., et al.
Publicado: (2012)

Recombinant humanised anti-HER2/neu antibody (Herceptin®) induces cellular death of glioblastomas
por: Mineo, J-F, et al.
Publicado: (2004)

HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer
por: Gijsen, Merel, et al.
Publicado: (2010)

Correction: Reciprocal Regulation of Annexin A2 and EGFR with Her-2 in Her-2 Negative and Herceptin-Resistant Breast Cancer
por: Shetty, Praveenkumar K., et al.
Publicado: (2012)

Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study
por: O’Shaughnessy, Joyce, et al.
Publicado: (2020)

Combination treatment with Grb7 peptide and Doxorubicin or Trastuzumab (Herceptin) results in cooperative cell growth inhibition in breast cancer cells
por: Pero, S C, et al.
Publicado: (2007)

HR+/HER2– Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review
por: Jerzak, Katarzyna J., et al.
Publicado: (2023)

Correction: HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer
por: Gijsen, Merel, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_c8aa0ksbom4pittthb88ui4q7m